AMY RICHARDSON: Open Payments
NPI 1972112720 · POPLAR BLUFF, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,035 in 68 payments from 15 companies in 2025. Trend: 2023 $964 · 2024 $1,118 · 2025 $1,035
Food & beverage: $967Education: $68
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $252 |
| Lilly USA, LLC | 17 | $119 |
| Novo Nordisk Inc | 6 | $110 |
| Astellas Pharma US Inc | 2 | $84 |
| Axsome Therapeutics, Inc. | 3 | $78 |
| Sumitomo Pharma America, Inc. | 3 | $69 |
| MAYNE PHARMA COMMERCIAL LLC | 4 | $65 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $56 |
| PFIZER INC. | 3 | $48 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $37 |
Products named: UBRELVY, Auvelity, ZEPBOUND, MYFEMBREE, VRAYLAR, XIFAXAN, Ozempic, QULIPTA.
Industry payments across MO — which companies pay providers there.
